Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. The AVXL news feed highlights company announcements related to its precision-medicine programs in Alzheimer’s disease, Parkinson’s disease dementia, Rett syndrome, schizophrenia, and other central nervous system (CNS) conditions.
News about Anavex often covers clinical trial milestones for its lead candidate ANAVEX ae2-73 (blarcamesine), including Phase 2a and Phase 2b/3 studies in Alzheimer’s disease, proof-of-concept data in Parkinson’s disease dementia, and trials in adult and pediatric Rett syndrome. Updates also address regulatory interactions, such as communications with the European Medicines Agency and the U.S. Food and Drug Administration regarding early Alzheimer’s disease, and the company’s plans to pursue re-examination procedures or further dialogue.
Investors and followers can also find coverage of ANAVEX ae3-71, which targets SIGMAR1 and M1 muscarinic receptors and has been studied in schizophrenia, as well as information on peer-reviewed publications, scientific conference presentations, and participation in initiatives like the ACCESS-AD consortium in Europe. Corporate developments, including financial results, business updates, and senior leadership appointments, are regularly reported.
This AVXL news page brings together these disclosures so readers can track how Anavex’s clinical data, regulatory discussions, collaborations, and corporate actions evolve over time. For those monitoring CNS drug development and precision-medicine approaches, the stream of press releases and related items offers context on the company’s progress and areas of focus.
Anavex Life Sciences Corp. (Nasdaq: AVXL) has announced a change in auditors from BDO USA LLP to Grant Thornton LLP, effective immediately. This decision follows a thorough evaluation process by the Audit Committee and is not due to any disagreements with BDO, which served the company for nine years. CEO Christopher U. Missling expressed gratitude to BDO for their service and optimism about the new partnership with Grant Thornton as Anavex progresses with its growth plans. The company specializes in developing therapeutics for neurodegenerative disorders.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3 pm ET. Christopher U. Missling, PhD, President and CEO, will present via a live audio webcast, accessible from the company's website. Anavex is focused on developing therapeutics for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Their lead candidate, ANAVEX®2-73, has shown promising results in clinical trials, indicating potential effectiveness for a range of CNS diseases.
Anavex Life Sciences Corp. (AVXL) reported its financial results for Q1 2022, revealing a net loss of $10.9 million, or $0.14 per share. Cash and cash equivalents stood at $151.1 million, slightly down from $152.1 million in the previous quarter. The company highlighted successful Phase 3 AVATAR study results for the Rett syndrome treatment, ANAVEX®2-73, and positive Phase 1 results for ANAVEX®3-71, which targets Frontotemporal Dementia. Additional clinical studies are planned for 2022 to expand the company's portfolio of neurodegenerative disorder treatments.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced supplemental information regarding the AVATAR Phase 3 trial of ANAVEX®2-73 (blarcamesine) for treating adult patients with Rett syndrome. Following a successful Phase 2 study, the AVATAR trial has updated endpoints approved by regulatory agencies in the UK and Australia. Anavex plans to approach the FDA for an approval pathway as no drugs are currently approved for Rett syndrome. The company’s candidate holds Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced a conference call scheduled for February 9, 2022, to discuss financial results for the fiscal quarter ending December 31, 2021.
The call will cover the company's growth strategy, following a successful Phase 2a trial for its lead drug candidate ANAVEX®2-73, which targets Alzheimer’s, Parkinson's, and Rett syndromes.
Management will also engage in a Q&A session, with further information available on their website.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced positive top-line results from its Phase 3 AVATAR trial of ANAVEX®2-73 in adult women with Rett syndrome. Key findings include statistically significant improvements in primary and secondary efficacy endpoints: 72.2% of patients showed improvement in RSBQ AUC (p = 0.037) compared to 38.5% on placebo. The study also indicated changes in biomarkers GABA and L-AAA. Anavex plans to engage with the FDA regarding the approval pathway, as there are currently no FDA-approved treatments for Rett syndrome.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced positive top-line results from its Phase 1 clinical trial of ANAVEX®3-71, a treatment for neurodegenerative diseases. The trial met primary and secondary safety endpoints, showing that the drug was well tolerated across all dose cohorts (5 mg to 200 mg) with no serious adverse events or dose-limiting toxicities. The drug exhibited linear pharmacokinetics and no significant food effects. Anavex plans to advance ANAVEX®3-71 into Phase 2 trials, aiming for a biomarker-driven program in treating Frontotemporal Dementia and Alzheimer's disease.
Anavex Life Sciences Corp. (AVXL) has announced significant leadership changes, promoting Walter E Kaufmann, M.D. to Chief Scientific Officer and appointing Edward R Hammond, M.D., M.P.H., PhD as Chief Medical Officer, effective immediately. Dr. Kaufmann brings extensive academic experience from institutions like Harvard and Johns Hopkins, while Dr. Hammond has over 15 years in clinical drug development from AstraZeneca. The company is focused on advancing its clinical candidates targeting neurodegenerative disorders, which shows potential for growth in patient care.
On January 5, 2022, Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U. Missling, PhD, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference from January 10-13, 2022. The presentation will focus on Anavex's innovative therapeutics for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. A webcast will be available on Anavex's website starting January 10, 2022. Anavex is known for its lead candidate, ANAVEX®2-73, which has shown promise in clinical trials for treating these conditions.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that President and CEO Christopher U. Missling, PhD, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at the Westin St. Francis Hotel in San Francisco, CA. Anavex is focused on developing therapeutics for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Their lead drug, ANAVEX®2-73 (blarcamesine), has shown promise in Phase 2 trials for Alzheimer’s and Parkinson’s disease dementia, indicating its potential to treat various CNS disorders. A live webcast of the presentation will be available online.